All In Biotech

Drug Trial Radar · NCT06081907

The Efficacy and Safety of IBI363 in Solid Tumors

A Prospective, Multi-cohort Study on Efficacy and Safety of IBI363 for Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Dec 25, 2023

Primary completion

Dec 1, 2026

Study completion Sep 1, 2028

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Xiangya Hospital of Central South University
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a prospective multi-cohort clinical study. The study is divided into two phases, Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3 dose-escalation design, with a preference for enrolling subjects with advanced non-small cell lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven cohorts.

Conditions

  • Advanced Solid Tumor

Interventions

  • IBI363Drug

    IBI363 is based on the "3+3" model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W.

  • IBI363Drug

    IBI363 is based on the "3+3" model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W.

  • IBI363Drug

    IBI363 is based on the "3+3" model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD.

  • IBI363Drug

    IBI363 is based on the "3+3" model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD.

  • IBI363Drug

    The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventTime frame: Up to 90 days post last dose
  2. ORRTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongchang Zhang

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.